- Study shows Chronix Biomedical liquid biopsy was 91% accurate at distinguishing patients with prostate cancer from patients with other medical conditions that may be associated with a higher PSA levels (e.g. Prostatitis or benign Prostate hyperplasia).
- There are approximately 1.2 million prostate biopsies a year in the US due to elevated PSA. Only 20% are found to be true cancer, almost 1 million biopsies were without any indication of a malignancy.
- Reducing unnecessary biopsies could reduce the $12 billion in estimated annual spending related to prostate cancer.
- Chronix Biomedical soon will be offering the first of its kind liquid biopsy test to aid doctors in their decision making whether patients with marginally elevated PSA would benefit a tissue biopsy or just being monitored
- Clinical Chemistry Abstract
- Clinical Chemistry Podcast
- Clinical Chemistry Transcript
- Vanderbilt University News
- New York Times Article about PSA Testing
Chronix Biomedical At ASCO
Listen to Chronix Biomedical Talk About a Study to Predict Treatment Outcomes in Cancer
Chronix Biomedical was honored to receive a Distinguished Abstract Award for it new blood test for transplant organ rejection using the Bio-rad Droplet Digital PCR technology.
Click here to view the 2008 Nobel Prize winner, Luc Montagnier, Chronix CEO, Howard Urnovitz and Prairie Gold General Partner, Mike Jerstad discuss how the academic, business and financial sectors can work together to fight breast cancer